Alnylam Pharmaceuticals Inc
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$369.00 | Zxknkmd | Pyyrlqj |
Narrow-Moat Alnylam Misses Q3 Revenue Estimates and Founding CEO Retires; Maintaining $158 FVE
Investors reacted negatively as Alnylam’s third-quarter results missed FactSet consensus estimates. During the quarter, Alnylam lost $1.72 per share, lower than FactSet consensus of a $1.59 loss per share. Nevertheless, Alnylam’s loss narrowed from negative $2.18 in the prior-year period. While sales grew 49% year over year to nearly $188 million, this was also behind FactSet estimates ($217 million). Additionally, management announced that its founding CEO, Dr. John Maraganore, will retire at the end of this year and transition CEO leadership to Alnylam’s current president and COO, Dr. Yvonne Greenstreet.